Press Releases - 2019-12-12

Date	Title	Company
12-Dec-2019	Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award	Vanda Pharmaceuticals Inc.
12-Dec-2019	Statement from FDA Deputy Commissioner Frank Yiannas on new findings and current status of the romaine lettuce E. coli O157:H7 outbreak investigation	U.S. Food and Drug Administration
12-Dec-2019	FDA authorizes first test to aid in newborn screening for Duchenne Muscular Dystrophy	U.S. Food and Drug Administration
12-Dec-2019	Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene	Vertex Pharmaceuticals
12-Dec-2019	CarThera signs a strategic collaboration with Lantheus for its SonoCloud device microbubbles	CarThera
12-Dec-2019	Syndivia Raises €1M Investment to Advance Its Tumour Microenvironment Drug Delivery Platform	Syndivia
12-Dec-2019	Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)	Sanofi
12-Dec-2019	OGT develops transformative constitutional NGS panel	Oxford Gene Technology
12-Dec-2019	Emergex Successfully Completes Preclinical Testing of its Lead ‘Set-Point’ Vaccine Candidate for Dengue Fever and Other Flaviviruses	Emergex Vaccines Holding Limited
12-Dec-2019	Darzalex®▼ (daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Ineligible for Transplant	the Janssen Pharmaceutical Companies of Johnson & Johnson
12-Dec-2019	Darzalex®▼ (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma	The Janssen Pharmaceutical Companies of Johnson & Johnson
12-Dec-2019	KITE, A GILEAD COMPANY, PRESENTS RESULTS FROM PIVOTAL ZUMA-2 TRIAL IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA	Kite, a Gilead Company
12-Dec-2019	PureTech Affiliate Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)	Vedanta Biosciences
12-Dec-2019	MorphoSys AG: Corporate Calendar 2020 (news with additional features)	MorphoSys AG
12-Dec-2019	Freeline appoints Julia P Gregory to its Board of Directors	Freeline
12-Dec-2019	Forendo Pharma Signs Important License and Collaboration Deal with Leading Pharma Company	Forendo Pharma
12-Dec-2019	Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors	Transgene
12-Dec-2019	Clevegen downregulates a range of major immuno-oncology (IO) checkpoints in MATINS cancer patients Biomarker analysis could guide future combination therapies with Clevegen	Faron Pharmaceuticals Oy
12-Dec-2019	Smart Cells Responds to ASA’s Ruling on Cells4Life’s Breach of Consumer Trust	Smart Cells
12-Dec-2019	Release of results for the full fiscal year 2018/19 (ending 30 September 2019) on 18 December 2019	Douglas GmbH